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Abstract
Background: Extrapulmonary tuberculosis (EPTB) poses diagnostic challenges due to the paucibacillary nature of
the disease. The immunochemistry-based MPT64 antigen detection test (MPT64 test) has shown promising results
for diagnosing EPTB in previous studies performed in low-resource settings, with higher sensitivity than microscopy
and culture. The aim of this study was to investigate the performance of the MPT64 test in a routine clinical setting
in a high-income low TB prevalence country.
Methods: Extrapulmonary samples sent for TB diagnostics to microbiology and pathology laboratories at three
regional tertiary care hospitals in Norway in a one-year period were included and subjected to the MPT64 test in
parallel to the routine TB diagnostic tests.
Results: Samples from 288 patients were included and categorised as confirmed TB cases (n = 26), clinically
diagnosed TB cases (n = 5), non-TB cases (n = 243) and uncategorised (n = 14), using a composite reference
standard (CRS). In formalin-fixed biopsies, the sensitivity (95% CI) of the MPT64 test, microscopy, PCR-based tests
pooled, and culture was 37% (16–62), 20% (4–48), 37% (16–62) and 50% (23–77), respectively, against the CRS. The
MPT64 test showed a good positive predictive value (88%) and an excellent specificity (99, 95% CI 92–100) in
formalin-fixed biopsies. In fine-needle aspirates, pus and fluid samples, the test performance was lower.
Conclusions: The MPT64 test was implementable in pathology laboratories as part of routine diagnostics, and
although the sensitivity of the MPT64 test was not better than culture in this setting, the test supplements other
rapid diagnostic methods, including microscopy and PCR-based tests, and can contribute to strengthen the
diagnosis of EPTB in formalin-fixed biopsies in the absence of culture confirmation.
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Background
While tuberculosis (TB) remains a global health problem,
the incidence in Norway and many other high-income
countries is low [1]. Still, diagnosis and control of TB dis-
ease poses significant challenges in high-income settings.
Although TB rates have been continuously declining in
the Norwegian-born population since the middle of the
past century, the overall TB incidence in Norway and
other high-income countries has remained relatively stable
over the last years because of immigration from TB preva-
lent countries [2–5]. Several studies also report that the
increase in foreign-born TB cases is associated with a rise
in the proportion of extrapulmonary TB (EPTB) [3, 5–7].
In the European region, EPTB has increased from 16,4%
of all TB cases in 2002 to 22,8% in 2016 [6, 8]. In the
Netherlands, England, Australia and Norway, EPTB cur-
rently accounts for as much as 40% of all TB cases [1, 2].
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Ida.Hoel@uib.no
1Centre for International Health, Department of Global Public Health and
Primary Care, University of Bergen, Bergen, Norway
2Department of Clinical Science, University of Bergen, Bergen, Norway
Full list of author information is available at the end of the article
Hoel et al. BMC Infectious Diseases          (2020) 20:130 
https://doi.org/10.1186/s12879-020-4852-z
The diagnosis of EPTB is challenging. Clinical and
radiological findings are often non-specific and the sen-
sitivity of routine TB diagnostic tests, including micros-
copy for acid fast bacilli (AFB) and culture, is low in
paucibacillary disease [9]. Culture also requires advanced
laboratory facilities, and results could be delayed up to 8
weeks. Globally, the use of rapid molecular tests for
detection of TB is increasing, albeit most commercially
available PCR-based tests are only approved for pulmon-
ary TB. The only World Health Organization (WHO)
endorsed PCR-based test for diagnosing EPTB, Xpert
MTB/RIF (Cepheid, Sunnyvale, CA), has shown variable
sensitivity in extrapulmonary samples [10] and is only
recommended for subgroups of EPTB [11]. A recently
launched new version, Xpert MTB/RIF Ultra (Xpert
Ultra), performs better in smear negative, culture posi-
tive sputum samples [12], but so far, few studies have
investigated its use in EPTB [13–18]. Histopathological
findings suggestive of TB may support the EPTB diagno-
sis, but these are also present in other diseases including
sarcoidosis and non-tuberculosis mycobacteria (NTM)
infections. The incidence of NTM infections is also
increasing in western countries [19–22]. Due to these
diagnostic challenges, a definite diagnosis of EPTB is
often difficult to obtain. Many EPTB patients are diag-
nosed clinically and EPTB is associated with diagnostic
delay [23–25]. Thus, better diagnostic tests are needed
to improve early case detection and management of
EPTB patients.
An immunochemistry-based test for detection of the
mycobacterial secreted protein MPT64 (MPT64 test)
from biopsies, fine-needle aspirates (FNAs) and fluid
samples has shown high sensitivity for diagnosing EPTB
in previous studies compared to culture and a TB spe-
cific nested-PCR [26–31]. The MPT64 test is robust and
fast, and can differentiate between NTM and TB disease,
as the MPT64 protein is specific for Mycobacterium
tuberculosis complex (MTBC) species, and not found in
NTM [32–34]. A recent study conducted in Zanzibar,
Tanzania, has also shown that the MPT64 test is imple-
mentable in a routine TB diagnostic setting in a TB
high-endemic low-resource country [35]. However, the
performance of the MPT64 test has not yet been evalu-
ated in a routine clinical setting in a low TB burden
high-income country. The objective of the study was to
evaluate performance of the MPT64 test and whether
the test would provide an added value to EPTB diagnos-
tics when implemented in routine TB diagnostics in the
high-resource health care system in Norway.
Methods
Sample inclusion
Formalin-fixed biopsies, FNAs and fluid samples sent for
TB diagnostics to microbiology and pathology laboratories
at three regional tertiary care hospitals (Haukeland Univer-
sity Hospital (HUH), Oslo University Hospital (OUH) and
Stavanger University Hospital (SUH)) from January 2015
until January 2016 were prospectively included in the study,
provided there was enough material left after routine diag-
nostics to prepare a minimum of one cell smear or tissue
section for the study (Fig. 1). Acellular fluid samples and all
samples from patients that had received TB treatment dur-
ing one year prior to the study, were excluded.
Because very few formalin-fixed biopsies from patients
with presumptive TB had been prospectively included, a
retrospective inclusion of biopsy specimens was also per-
formed. At HUH and SUH, all samples included in the
study from the microbiology laboratories were cross-
checked with the pathology laboratory registers to see if
the same sample, or a different sample material collected
from the same location at the same time, had been sent
to the pathology laboratories. At OUH, a list of all biop-
sies sent for TB diagnostics to the microbiology labora-
tory during 2015 was cross-checked with the pathology
register to find the samples that had been sent for both
departments. Based on these searches, formalin-fixed
biopsies from the pathology departments were included
if they showed any type of inflammation or necrosis.
Biopsies with a histopathological diagnosis other than
TB (e.g. malignancy) or no pathological findings were
not included as these samples will not be subjected to
TB specific tests at the pathology laboratory in a routine
clinical setting.. Additionally, all formalin-fixed biopsies
that had been subjected to a TB specific nested-PCR as
part of routine diagnostics at Department of Pathology
at HUH, were retrospectively included.
Sample processing and routine TB diagnostic procedures
All samples were subjected to routine TB diagnostics at
the inclusion hospitals according to local diagnostic
algorithms. At the microbiology laboratories, FNAs in
saline and fluid samples were used unconcentrated if
volume < 10mL and concentrated by centrifugation
before resuspension of sediment in saline if the sample
volume was > 10 mL. Biopsy specimens were mechanic-
ally homogenized and resuspended in saline. Cell smears
were stained using the Ziehl-Neelsen or Auramine
method for detection of AFB. For the study, a minimum
of one cell smear from fluid samples was prepared on a
Superfrost glass, air-dried for 20 min, fixed in absolute
ethanol for 20 min and stored at room temperature. A
standard NALC-NaOH decontamination procedure was
performed on the remaining sample material if the sample
was non-sterile, before appropriate sample volumes were
seeded in liquid medium (BACTEC MGIT), and for most of
the samples, also onto solid medium (Lowenstein-Jensen).
At HUH, all lymph node specimens, sterile fluids and aspi-
rates and most biopsies were cultured both before and after
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NALC-NaOH decontamination, and lymph node specimens
were also cultured at 28 °C. If PCR was requested by the
clinician, a 1-step PCR-based tests (1-step PCR) including
Cobas Taqman MTB (Roche, Switzerland) at OUH, Abbott
Real Time MTB (Abbott, United States) at SUH and Geno-
type MTBDR plus (Hain Lifescience, Germany) at HUH,
was performed. All samples with a remaining volume of >
0.5mL, were stored at − 80 °C for later analysis with Xpert
Ultra.
At the pathology laboratories, biopsy specimens were
routinely fixed in PBS buffered formalin and embedded
in paraffin before tissue sections were prepared for hist-
ology. Fine-needle aspiration from lymph nodes was
performed by local clinicians or pathologists and cell
smears for cytology were directly prepared and fixed
after sample collection. If microscopy for AFB was
requested by the pathologist, the Ziehl-Neelsen (HUH,
SUH), Auramine (OUS) or Fite Faraco [36] (OUS) method
was used. Additionally, a previously developed in-house
nested-PCR (n-PCR) for detection of the MTBC-specific
IS6110 sequence in DNA extracted from archived material
[37] was also performed on the samples as part of routine
diagnostics at HUH only, if requested by the pathologist.
Xpert ultra
Xpert Ultra was performed on all the frozen sample ma-
terial during the autumn 2018, except for pleural fluid
samples, which were only subjected to Xpert Ultra if TB
was mentioned as a differential diagnosis on the request
form or in patient records. This was done to exclude
clinically irrelevant samples, as many pleural fluid sam-
ples are routinely sent for TB diagnostics, even when the
Fig. 1 Flow chart of study design and sample inclusion. Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction; AFB, acid fast bacilli.
1Uncategorised cases included 3 patients who died, 2 patients that did not show for clinical controls, 8 patients that had not been given a
definite diagnosis 8 months after inclusion of samples ended, but for whom TB could not be ruled out either because they have previously been
treated for TB or because histopathology showed necrotising granulomas and giant cells in the samples included. The last patient was given a
clinical TB diagnosis, but the sample included in the study showed no pathology and may be non-representative of the site of infection
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pre-test probability of TB is very low. Samples were
thawed at room temperature and processed according to
the manufacturer’s protocol. All but two samples (both
volume 0.25 mL) had a sample volume of minimum 0.5
mL. Samples with volume < 0.7 mL (n = 20) were added
sample reagent to sample in a 3:1 ratio, whereas a ratio
of 2:1 was used for samples with a volume of 0.7 mL or
more (n = 28).
Immunostaining with MPT64
The MPT64 test was performed by a laboratory technician
in parallel to routine TB diagnostics at Department of
Pathology at HUH. The request form with clinical infor-
mation, sometimes including results of TB diagnostic
tests, was available to the technician. The test was per-
formed using an in-house polyclonal rabbit anti-MPT64
antibody at 1:250 dilution together with the Dako Envision
+ System-HRP kit (Agilent, Santa Clara, CA), according to
the manufacturer’s protocol with some modifications as
earlier described [26, 28]. Briefly, tissue sections were
deparaffinized with xylene, before tissue sections and cell
smears were rehydrated through decreasing grades of al-
cohol. Microwave antigen retrieval in citrate buffer, pH
6.2, was then performed on tissue sections only. Further,
tissue sections and cell smears were washed in distilled
water for 10min and incubated with hydrogen peroxide
for 20min. The primary anti-MPT64 antibody was applied
and the slides were incubated for 60min, before horse-
radish conjugated secondary anti-rabbit antibody was
applied for 45min. Thereafter, the substrate (3-amino-9-
ethylcarbazol) was added to the slides for 10min for
smears and 15min for biopsies, followed by counterstain-
ing with Mayer’s haematoxylin and mounting with Immu-
Mount (Thermo Fisher Scientific, United States). Slides
were washed with wash buffer (0.05mol/L Tris/HCl buff-
ered saline with 0.05% Tween 20, pH 7.6) between incuba-
tion steps.
Evaluation of immunostaining
A laboratory technologist was trained to screen the
MPT64 test stained cell smears prepared from fluid
samples. Screening was performed at a total magnifica-
tion of 200x and more detailed evaluation at 400x. Fluid
samples screened possibly positive were examined by a
designated pathologist, who also evaluated all biopsies
and FNAs, according to a previously developed guideline
for interpretation [35]. Briefly, a sample was positive if a
minimum of two granular red-brown coloured spots,
either observed intracytoplasmic in inflammatory cells
or extracellularly in necrotic material, were present in
the sample. If only one typical spot was present, or if the
staining was not strongly granular, the test was evaluated
as weakly positive. No staining, nuclear staining or extra-
cellular granular staining in non-necrotic areas were
interpreted as negative. Clinical information on the
request form, which sometimes included information
about results of routine TB diagnostics, was available to
the pathologist.
Categorisation of samples and patients according to a
composite reference standard
A composite reference standard (CRS), including both
microbiologically confirmed TB and clinically diagnosed
TB, was used to define a TB case. Results of routine TB
diagnostic tests and cyto/histopathological examination
were obtained from the laboratory information systems.
Medical records for all patients with culture and PCR
negative samples were checked for a clinical TB diagno-
sis 8 months after the inclusion of samples had finished.
According to the CRS, a patient was defined as a con-
firmed TB case if a culture and/or PCR (1-step PCR
and/or n-PCR) positive sample was registered during the
inclusion period or on a repeat sample until 8 months
afterwards. Culture and/or PCR positive samples were
classified as confirmed samples from confirmed TB cases,
whereas culture and PCR negative samples from patients
that were diagnosed with microbiologically confirmed
TB within 8 months after end of inclusion, were classi-
fied as unconfirmed samples from confirmed TB cases. A
patient that had been given a clinical TB diagnosis and
successfully completed a full course of TB treatment,
was defined as a clinically diagnosed TB case. Patients
with culture and PCR negative samples that improved
without treatment, or were given a diagnosis other than
TB, or had a negative interferon-gamma-release assay, or
had stable symptoms and negative results of TB diagnos-
tics at repeated controls until 8 months after the inclu-
sion had finished, were defined as non-TB cases. Patients
that did not fit into any of these categories were classi-
fied as uncategorised cases.
Statistical analysis
Test performance was evaluated using one sample per
case. When multiple samples were included from one
case, the first sample collected from non-TB cases and
the first confirmed TB sample collected from TB cases
was chosen for analysis. For TB cases with multiple
unconfirmed samples included, the sample with cyto/
histopathological findings most strongly suggestive of
TB was chosen. Sensitivity, specificity and accuracy were
calculated using the CRS as reference method.
Results
Clinical samples
A total of 465 samples received for TB diagnostics at the
inclusion hospitals were consecutively sent to the HUH
during the study period (Fig. 1). Additionally, 97 samples
were retrospectively included from the same hospitals.
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After exclusion of 202 samples for various reasons, the
remaining 360 samples from 288 patients were classified
using the CRS. Twenty-six patients were confirmed TB
cases, 5 clinically diagnosed TB cases, 243 non-TB cases
and 14 uncategorised cases. Uncategorised cases were
excluded, leaving samples from 274 patients for analysis.
Clinical characteristics for the included samples are
shown in Table 1. Pleural fluid was the most common
sample type. The MPT64 test was performed on all
samples, whereas the type and number of routine TB
diagnostic tests performed on the samples varied. HIV
status was unknown for the study participants.
Among the 97 retrospectively included formalin-fixed
biopsies, 13 biopsies were included because they had
been subjected to a TB specific n-PCR at the pathology
laboratory at HUH, due to histopathological findings
suggestive of TB. These samples had not been sent for
TB diagnostics at the microbiology laboratory and TB
was not mentioned as a differential diagnosis on the
request form. Four of 13 samples were n-PCR positive,
and TB was thus, an unexpected finding in these cases.
MPT64 test performance compared to routine TB
diagnostics and Xpert ultra
Biopsy specimens
Using the CRS, the sensitivity (95% CI) of the MPT64 test
in formalin-fixed biopsies was 37% (16–62), compared to
20% (4–48), 37% (16–62) and 50% (23–77) for micros-
copy, PCR-based tests pooled and culture respectively
(Tables 2 and 3). Against PCR (1-step PCR and n-PCR
pooled) as a reference standard, the sensitivity of the
MPT64 test was 71% (5/7, 95% CI 29–96). However, in
PCR negative, culture positive biopsies (n = 6), the MPT64
test was negative in all samples. One of the 69 non-TB
biopsies was MPT64 test positive, yielding a positive pre-
dicitive value of 88% (7/8 MPT64 test positive biopsies
were from TB cases) and an excellent specificity of 99%
(95% CI 92–100). Granulomatous inflammation with
necrosis, the most specific histopathological finding sug-
gestive of TB, was present in 13/19 biopsies from TB cases
and 13/69 non-TB biopsies (Table 4). This gives histo-
pathology a sensitivity, specificity and positive predicitive
value of 68% (43–87), 81% (70–90) and 50% (36–64) re-
spectively against the CRS. Among biopsies from non-TB
cases, 5 samples were bacteriologically confirmed NTM
infections and another 3 samples came from patients with
a probable, though not confirmed, NTM infection. The
MPT64 test was negative inn all these samples.
Fine needle-aspirates and fluid samples
Abundant non-specific staining was observed in the cell
smears prepared from FNAs, pus and fluid samples, and
the MPT64 test performance was lower in these materials
compared to the biopsies. Using the CRS, the sensitivity
and specificity of the MPT64 test in lymph node FNAs
was 29% (95% CI 4–71) and 50% (95% CI 7–93) respect-
ively. Cytopathological findings suggestive of TB had low
Table 1 Characteristics of samples included (one sample per patient)
TB cases1 non-TB cases
n = 31 n = 243
Sample material
Lymph node aspirates 7 4
Lymph node biopsies 7 17
Other biopsies 12 52
Pus 2 13
Pleural fluid 3 133
Ascites 0 8
Pericardial fluid 0 3
Synovial fluid 0 10
Other fluids 0 3
Number of samples
per patient2
1 sample 24 200
2 samples 6 33
3 samples 0 6
4 samples 1 3





n = 88 n = 11 n = 175




Microscopy3 59 9 43
1-step PCR 32 6 8
Nested-PCR 12 4 1
Culture 68 9 83
Sample only sent to the
microbiology laboratory
N/A N/A 92
Microscopy N/A N/A 51
1-step PCR N/A N/A 12
Culture N/A N/A 92
Sample only sent to the
pathology laboratory
20 2 N/A
Microscopy 4 0 N/A
Nested-PCR 17 1 N/A
Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction, N/A, not applicable
1Includes 5 clinically diagnosed patients
2Number of samples per patient included at different time points. Patients
with the same material from the same site (n = 27), different material from the
same site (n = 13), material from different locations (n = 6), material from different
locations, multiple samples collected from some of these locations (n = 4)
3Microscopy performed at pathology and/or microbiology laboratory. A
sample with discordant microscopy results between the laboratories (n = 2) is
registered as positive
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sensitivity and specificity for diagnosing TB. In pus and
fluid samples, the sensitivity of all tests methods was diffi-
cult to evaluate due to few TB cases. All three pleural
fluids from TB cases were culture positive and negative
with all other tests. Two pus samples from TB cases were
included. One was microscopy negative and positive with
culture, 1-step PCR, Xpert Ultra and the MPT64 test,
whereas the other sample was negative with all tests.
Many non-TB pus and fluid samples were interpreted as
weakly positive (n = 33) or positive (n = 3), and the specifi-
city of the MPT64 test was 80% (95% CI 72–86) and 69%
(95% CI 39–91) in fluid and pus samples, respectively.
Head-to-head comparison of various diagnostic methods
As the number of TB diagnostic tests performed on the
samples varied greatly, the diagnostic performance of
the different tests was also evaluated based on head-to-
head comparisons (Table 5). There was no difference in
the overall test performance between microscopy and
the MPT64 test, which both detected the same number
of TB cases as 1-step PCR, and fewer TB cases than n-
PCR, Xpert Ultra and culture. Further, the subgroup
comparisons of culture, 1-step PCR, microscopy and the
MPT64 test showed that some samples were positive in
one test and negative in the other and vice versa. The
MPT64 test was positive in 4 microscopy negative sam-
ples, 2 1-step PCR negative samples and 3 culture negative
samples, indicating added value of combining various TB
diagnostic tests.
Discussion
This is the first study in which the MPT64 test, an
immunochemistry-based test for diagnosing EPTB, has
been implemented in parallel to routine TB diagnostics
in a low TB prevalence country with a high-resource
health care system. Using a CRS that included clinically
Table 2 Results of routine TB diagnostic tests, Xpert Ultra and the MPT64 test performed on samples
Positive samples/total samples (%)
Number of cases Micro-scopya Culture 1-step PCR Nested-PCR Xpert Ultra MPT64 test
TB cases
All samples 31 6/27 (22) 16/26 (62) 6/18 (33) 7/11 (64) 4/7 (57) 10/31 (32)
Lymph node biopsies 7 1/6 (17) 2/6 (33) 0/5 (0) 2/2 (100) N/A 3/7 (43)
Other biopsies 12 2/9 (22) 5/8 (63) 1/7 (14) 4/6 (67) N/A 4/12 (33)
Pus samples 2 0/2 (0) 1/2 (50) 1/1 (100) N/A 1/2 (50) 1/2 (50)
Lymph node aspirates 7 3/7 (43) 5/7 (71) 4/4 (100) 1/3 (33) 3/4 (75) 2/7 (29)
Fluid samples 3 0/3 (0) 3/3 (100) 0/1 (0) N/A 0/1 (0) 0/3 (0)
Confirmed TB case -confirmed sample 22b 5/19 (26) 16/17 (94) 6/13 (46) 7/9 (78) 4/5 (80) 8/22 (36)
Culture positive sample 16 4/16 (25) 16/16 (100) 5/12 (42) 2/4 (50) 4/5 (80) 3/16 (19)
Culture positive, PCR positive sample 6 3/6 (50) 6/6 (100) 5/5 (100) 2/2 (100) 3/3 (100) 3/6 (50)
Culture positive, PCR negative sample 8 1/8 (13) 8/8 (100) 0/7 (0) 0/2 (0) 1/2 (50) 0/8 (0)
1-step PCR positive sample 6 4/6 (67) 5/6 (83) 6/6 (100) 1/1 (100) 3/3 (100) 4/6 (67)
Nested-PCR positive sample 7 1/4 (25) 2/2 (100) 1/1 (100) 7/7 (100) 1/1 (100) 5/7 (71)
Confirmed TB case -unconfirmed sample 4 0/3 (0) 0/4 (0) 0/3 (0) N/A N/A 2/4 (50)
Clinically diagnosed TB case 5 1/5 (20) 0/5 (0) 0/2 (0) 0/2 (0) 0/2 (0) 0/5 (0)
Non-TB cases
All samples 243 7/139 (5) 0/226 (0) 0/40 (0) 0/24 (0) 1/41 (2) 39/243 (16)
Lymph node biopsies 17c 1/13 (8) 0/14 (0) 0/4 (0) 0/4 (0) 0/2 (0) 0/17 (0)
Other biopsies 52d 2/35 (6) 0/40 (0) 0/16 (0) 0/17 (0) 1/8 (13) 1/52 (2)
Pus samples 13e 3/13 (23) 0/13 (0) 0/4 (0) 0/1 (0) 0/8 (0) 4/13 (31)
Lymph node aspirates 4f 1/2 (50) 0/2 (0) 0/2 (0) 0/2 (0) 0/1 (0) 2/4 (50)
Fluid samples 157 0/76 (0) 0/157 (0) 0/14 (0) N/A 0/22 (0) 32/157 (20)
Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction
aMicroscopy performed at microbiology laboratory and/or pathology laboratory. A sample with discordant microscopy results between the laboratories (n = 2) is
registered as microscopy positive
bOne of the nested-PCR positive patients was not started on TB treatment, and only followed by controls
c6 cases of NTM infection (2 NTM culture positive, 1 NTM specific PCR positive, 3 given a clinical diagnosis)
d2 cases of NTM infection (2 NTM specific PCR positive)
e3 cases of NTM infection (3 microscopy and NTM culture positive)
f1 case of NTM infection (microscopy, NTM culture and NTM specific PCR positive. This case was also MPT64 positive)
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diagnosed TB cases, the test had a sensitvity (95% CI) of
37% (16–62) in formalin-fixed biopsies, compared to
37% (16–62) and 50% (23–77) for PCR-based tests
pooled and culture, respectively. The specificity of the
test was excellent (99, 95% CI 92–100) in formalin-fixed
biopsies. In cell smears prepared from FNAs, pus and
fluid samples, the test performance was low. Culture was
found to be the most sensitive method for diagnosing
TB in the study, with a disadvantage of long turnaround
time. The study revealed that in this low TB incidence
setting, many EPTB cases are incidentally detected based
on histopathological findings in biopsy specimens that










All samples (n = 274)
Microscopy 166 22 (9–42) 95 (90–98) 83
Culture 252 62 (41–80) 100 (98–100) 96
PCR (1-step PCR and n-PCR pooled) 87 44 (26–65) 100 (94–100) 83
Xpert Ultra 48 57 (18–90) 98 (87–100) 92
MPT64 test 274 32 (17–51) 84 (79–88) 78
Lymph node biopsies (n = 24)
Microscopy 19 17 (0–64) 92 (64–100) 68
Culture 20 33 (4–78) 100 (77–100) 80
PCR (1-step PCR and n-PCR pooled) 15 29 (4–71) 100 (63–100) 67
Xpert Ultra 2 N/A 100 (16–100) –
MPT64 test 24 43 (10–82) 100 (80–100) 83
All biopsies (n = 88)
Microscopy 63 20 (4–48) 94 (83–99) 76
Culture 68 50 (23–77) 100 (93–100) 90
PCR (1-step PCR and n-PCR pooled) 57 37 (16–62) 100 (91–100) 79
Xpert Ultra 10 N/A 90 (56–100) –
MPT64 test 88 37 (16–62) 99 (92–100) 85
Lymph node aspirates (n = 11)
Microscopy 9 43 (10–82) 50 (1–99) 44
Culture 9 71 (29–96) 100 (16–100) 78
PCR (1-step PCR and n-PCR pooled) 9 67 (22–96) 100 (29–100) 78
Xpert Ultra 5 75 (19–99) 100 (3–100) 80
MPT64 test 11 29 (4–71) 50 (7–93) 36
Pus samples (n = 15)
Microscopy 15 0 (0–84) 77 (46–95) 67
Culture 15 50 (1–99) 100 (75–100) 93
PCR (1-step PCR and n-PCR pooled) 6 100 (3–100) 100 (48–100) 100
Xpert Ultra 10 50 (1–99) 100 (63–100) 90
MPT64 test 15 50 (1–99) 69 (39–91) 67
Fluid samples (n = 160)
Microscopy 79 0 (0–71) 100 (95–100) 96
Culture 160 100 (29–100) 100 (98–100) 100
PCR (1-step PCR and n-PCR pooled) 15 0 (0–98) 100 (77–100) 93
Xpert Ultra 23 0 (0–98) 100 (85–100) 96
MPT64 test 160 0 (0–71) 80 (72–86) 78
Abbreviations: PCR, polymerase chain reaction; CI, confidence interval
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have not been sent for culture in parallel. Histopatho-
logical findings alone cannot confirm a TB diagnosis, and
in these cases, the MPT64 test can supplement other rapid
tests, including microscopy and n-PCR. This test is less
prone to contamination than PCR and, in contrast to
microscopy, can differentiate between MTBC and NTM
infections. Thus, the MPT64 test may strengthen the TB
diagnosis in a pathology laboratory in the absence of cul-
ture confirmation.
The MPT64 test performance was lower in the present
study compared to previous studies [28–30, 35]. Against
a CRS, the overall sensitivity was 32% (95% CI 17–51)
for the MPT64 test, compared to 67–100% in previous
studies [28–30, 35]. The use of different composite refer-
ence standards and variable TB prevalence across the
studies may contribute to this variation. All previous
studies were conducted in high TB burden settings, in
which a higher pre-test probability of TB combined with
potentially more advanced stage of TB disease at the
time of diagnosis, may lead to higher test sensitivity. Still,
also when using culture as a reference standard, the overall
MPT64 test sensitivity was lower (19, 95% CI 4–46)
compared to previous studies (75–100%) [26, 28, 30, 35,
37]. This could partly be explained by different procedures
for culture used across the studies. Apportioning of smaller
sample volumes for culture and long transportation time to
the TB laboratory, potentially reducing the viability of the
bacilli, may have reduced the sensitivity of culture in previ-
ous studies [35]. In most of the previous studies, all samples
were decontaminated and seeded onto only 1 tube of solid
medium, whereas 2–8 culture tubes per sample were used
for most samples in the present study, including culturing
of material not treated with NALC-NaOH for many
samples. These factors can lead to increased sensitivity of
culture in our study, especially in paucibacillary specimens
with non-uniform distribution of bacilli. Further, the use of
different reference standards makes it challenging to com-
pare the studies. For validation of the MPT64 test, n-PCR
has been used as a reference standard in most previous
studies, yielding a sensitivity of 72–100% [26–29, 31, 35]. In
the present study, n-PCR was only performed on a sub-
group of samples and could not be used for validation
alone. However, when using n-PCR as a reference standard
in this subgroup, the sensitivity of the MPT64 test was 71%
Table 4 Cyto/histopathological findings in biopsy and fine-needle aspirate samples
TB cases Non-TB cases
Confirmed sample Unconfirmed sample Clinically diagnosed sample Total TB cases
Histomorphology, biopsies (n = 88) n = 13 n = 3 n = 3 n = 19 n = 69
Granulomatous inflammation
with necrosis
9 3 1 13 13
Granulomatous inflammation
without necrosis












Foreign body granuloma 1
Lymph node hyperplasia 1
Mesothelial proliferation 1
No pathology 1




Abundant necrosis 3 3 1
Fluid background, mostly RBCs 1 1 1
Subacute or chronic inflammation 1 1 1
Acute inflammation 1 1
Abbreviations: TB, tuberculosis; FNA, fine-needle aspirate
Hoel et al. BMC Infectious Diseases          (2020) 20:130 Page 8 of 11
(95% CI 29–96). This is close to previous findings. More-
over, all culture positive samples were n-PCR positive in
previous studies, whereas the present study included several
culture positive, but PCR negative samples (n = 8). The
MPT64 test was negative in all these culture positive, PCR
negative samples. Assuming that culture positive, PCR
negative samples have a lower bacterial load than culture
positive, PCR positive samples, these results indicate that
the MPT64 test is not sensitive enough to detect samples
with very low bacterial load. However, the long turnout
time of culture does not help clinicians to make a timely
diagnosis. Further, although culture performed under opti-
mal conditions is the most sensitive method for diagnosing
EPTB in the present study, TB culture facilities are not
available in most TB endemic areas, in which TB diagnos-
tics are most needed.
The specificity of the MPT64 test in biopsy specimens
was very high and comparable to results observed in
previous studies, whereas the specificity in cell smears
prepared from FNAs, pus and fluid samples was lower.
In lymph node FNAs, the specificity was only 50%, How-
ever, this was based on only two MPT64 test positive
non-TB cases of a total of four non-TB cases, which
gives low power to the estimate. In pus and fluid sam-
ples, non-specific false positive staining was observed in
a large proprotion of the smears and made interpretation
challenging. The non-specific staining may have been
caused by suboptimal sample handling at the microbiol-
ogy laboratories where samples could be stored cold for
more than one day before preparation of smears, as indi-
cated by cell lysis in many samples. Long storage time
may have affected the antigen integrity and increased non-
specific binding. In contrast, smears in previous studies
were prepared immediately after sample collection.
The low specificity of the test in cell smears has a
greater impact in this low prevalence setting compared
to a high prevalence setting because more false positive
cases and unecessary treatment must be accepted for
every true positive case detected. Thus, the results of the
present study indicate that the MPT64 test is not useful
for diagnosis of EPTB in cell smears. In biopsy speci-
mens, on the other hand, the test was highly specific. It
was negative in clinically relevant non-TB samples with
various types of inflammation and in all samples from
patients with NTM infections. NTM infection is an
important differential diagnosis to EPTB, as 31% of the
microbiologically confirmed mycobacterial infections
were NTM in the present study.
There are limitations to the study. The low number of
TB cases gives low power to sensitivity estimates.. Fur-
ther, the exlusion of culture and PCR negative samples
because information about clinical TB diagnosis was not
available (Fig. 1), in addition to the exclusion of biopsies
with a histopathological diagnosis other than TB or no
pathological findings, leads to a selection bias in favour
of samples with a higher pre-test probability of TB,
which could affect specificity estimates. As the study was
designed to evaluate the MPT64 test performance in a
routine setting, we did not intervene in sample handling
or TB diagnostic algorithms at the inclusion sites, lead-
ing to many suboptimally prepared samples for the
MPT64 test. Samples from patients with presumptive






















Nested-PCR+ Nested-PCR- Culture + Culture -
n = 10 n = 21 n = 6 n = 21 n = 6 n = 12 n = 7 n = 4 n = 16 n = 10
Microscopy + 2 4
Microscopy - 4 17
1-step PCR + 4 2 4 2
1-step PCR - 2 10 2 9
Nested-PCR + 5 2 1 3 1 0
Nested-PCR - 0 4 0 4 0 1
Culture + 3 13 4 12 5 7 2 2
Culture - 3 7 2 7 1 5 0 2
Xpert Ultra + 2 2 2 2 3 0 1 1 4 0
Xpert Ultra - 0 3 0 3 0 1 0 1 1 2
Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction
1TB cases include both microbiologically confirmed TB cases (n = 26) and clinically diagnosed TB cases (n = 5)
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EPTB were often not sent for TB diagnostics both to
microbiology and pathology laboratories, as would have
been expected according to good clinical practice. Not
only may this lead to diagnostic delay since the available
diagnostic tools are not fully utilized in difficult-to-
diagnose cases, but it also makes it difficult to compare
test performance in the present study because the types
and number of tests performed per sample varied
greatly. Hence, more controlled validation studies with
larger cohorts are needed to fully asses MPT64 test per-
formance in a low TB incidence high-resource setting.
Conclusions
The diagnosis of EPTB is challenging in a high-resource,
low-TB incidence country. The awareness of TB is often
low and routine TB diagnostic tests are not able to iden-
tify all EPTB cases. The MPT64 antigen detection test
has a good positive predictive value and an excellent
specificity in formalin-fixed biopsies and is implementa-
ble in pathology laboratories. In the absence of culture,
the MPT64 test may contribute to strengthen the TB
diagnosis in formalin-fixed biopsies when used in com-
bination with microscopy and PCR-based tests, and thus,
has an added value in TB diagnostics in this setting.
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